This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valero, V. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Valero, V. Articles by Hortobagyi, G. N.

Locally Advanced Breast Cancer

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence: Vicente Valero, M.D., Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas Medical Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Telephone: 713-792-2817; Fax: 713-794-4385.

Locally advanced breast cancer encompasses a heterogeneous collection of breast neoplasms and constitutes approximately 10%-20% of the newly diagnosed breast cancers. These cancers may have widely different clinical and biological characteristics. Patients with these tumors may be classified as stage IIB, III or IV breast cancer according to the American Joint Committee for Cancer Staging and End Results Reporting (TNM classification). Multidisciplinary therapy has become the treatment of choice for these patients. Primary or neoadjuvant chemotherapy followed by locoregional therapy, either surgery and/or radiotherapy, and postoperative systemic chemotherapy is now an accepted strategy. More than 70% of patients achieve an objective response (including pathological complete remission in 10%-25% of cases), and many patients experience downstaging through primary chemotherapy. Breast conservation is possible in 10%-40% of patients with locally advanced breast cancer; almost all patients initially are rendered disease-free, and long-term local control is achieved in over 70% of these patients. Primary chemotherapy is the initial choice of treatment for patients with locally advanced tumors, but it is unclear what the optimal sequence of subsequent therapies should be, whether one or two local treatment modalities are necessary, and whether any or different postoperative chemotherapy is needed. The efficacy of primary chemotherapy was demonstrated in several large prospective studies in patients with locally advanced breast cancer. The natural history of this disease was changed dramatically by the introduction of these combined modality therapies. Five-year disease-free survival rates of 35%-70% are commonly reported, and about 25%-40% of patients will survive beyond 10 years without recurrence. In summary, multidisciplinary therapy that includes primary chemotherapy provides appropriate local control and the possibility of breast conservation therapy; it increases surgical resectability and survival rates in patients with locally advanced breast cancer. The role of new innovative therapeutic strategies such as high-dose chemotherapy, with hematopoietic stem cell rescue, new cytotoxic agents and higher dose-intensity therapy is currently under evaluation in patients with locally advanced breast cancer.

Key Words. Breast cancer • Locally advanced • Inflammatory • Chemotherapy • Surgery • Radiotherapy • Breast conservation

This article has been cited by other articles:

				S. D. Costa, S. Loibl, M. Kaufmann, D.-M. Zahm, J. Hilfrich, J. Huober, H. Eidtmann, A. du Bois, J.-U. Blohmer, B. Ataseven, et al. Neoadjuvant Chemotherapy Shows Similar Response in Patients With Inflammatory or Locally Advanced Breast Cancer When Compared With Operable Breast Cancer: A Secondary Analysis of the GeparTrio Trial Data J. Clin. Oncol., January 1, 2010; 28(1): 83 - 91. [Abstract] [Full Text] [PDF]

				M. T. Ionta, F. Atzori, M. C. Deidda, V. Pusceddu, S. Palmeri, B. Frau, M. Murgia, M. Barca, L. Minerba, and B. Massidda Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response ( Oncologist, November 1, 2009; 14(11): 1051 - 1060. [Abstract] [Full Text] [PDF]

				J.-P. Delille, P. J. Slanetz, E. D. Yeh, E. F. Halpern, D. B. Kopans, and L. Garrido Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study Radiology, July 1, 2003; 228(1): 63 - 69. [Abstract] [Full Text] [PDF]

				P. Therasse, L. Mauriac, M. Welnicka-Jaskiewicz, P. Bruning, T. Cufer, H. Bonnefoi, E. Tomiak, K. I. Pritchard, A. Hamilton, and M.J. Piccart Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study J. Clin. Oncol., March 1, 2003; 21(5): 843 - 850. [Abstract] [Full Text] [PDF]

				R. A. Brito, V. Valero, A. U. Buzdar, D. J. Booser, F. Ames, E. Strom, M. Ross, R. L. Theriault, D. Frye, S.-W. Kau, et al. Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience J. Clin. Oncol., February 1, 2001; 19(3): 628 - 633. [Abstract] [Full Text] [PDF]

				A. H. Honkoop, S. A. Luykx-de Bakker, K. Hoekman, S. Meyer, O. W.M. Meyer, C. J. van Groeningen, P. J. van Diest, E. Boven, E. van der Wall, G. Giaccone, et al. Prolonged Neoadjuvant Chemotherapy with GM-CSF in Locally Advanced Breast Cancer Oncologist, April 1, 1999; 4(2): 106 - 111. [Abstract] [Full Text]